Contagious Conversations

03: All Lives Have Equal Value


Listen Later

Dr. Sue Desmond-Hellmann is a physician, scientist and philanthropist who has devoted her career to improving the human condition. Trained as an oncologist, she spent 14 years at biotech firm Genentech, where she led the development of Avastin and Herceptin, two of the first gene-targeted therapies for cancer. Today, as CEO of the Bill & Melinda Gates Foundation, Dr. Desmond-Hellmann leads the organization's vision for a world where every person has the opportunity to live a healthy and productive life.

In this episode, Dr. Sue Desmond-Hellmann shares her work as a pioneer in healthcare for more than 30 years, including her efforts to drive major developments toward the eradication of disease, poverty and inequity.

For more information and full episode transcription go to Contagious Conversations (www.cdcfoundation.org/conversations).

Key Takeaways:

[1:03] The biggest influencers in Dr. Sue Desmond-Hellmann´s career.

[2:50] How did Dr. Sue Desmond-Hellmann become the leader of one of the world largest health philanthropies?

[5:26] Investing in human capital can translate into economic success.

[6:23] The case of Ethiopia.

[7:06] The most important value in public-private partnerships.

[8:32] How a "volume guarantee" enhances philanthropy.

[10:02] Encouraging companies to pay attention to where their future customers are going to be.

[10:55] How does Dr. Desmond-Hellmann relax and recharge?

[12:03] The importance of taking thoughtful risks in philanthropy.

[13:11] Big bold collaborations can improve and save more lives.

[16:02] What areas of global health is Dr. Hellmann most optimistic about?

[16:50] HIV and malaria.

[18:47] Tuberculosis today is one of the hardest diseases to tackle.

[20:13] TB vaccine is closer than ever.

[20:28] Dr. Desmond-Hellmann shares her thoughts about a nationalistic perspective.

[22:30] What keeps her up at night? She worries about people getting the wrong information about vaccines.

[24:50] Dr. Desmond-Hellmann’s biggest challenge at the Gates Foundation.

[25:46] It is not easy to change systems.

[27:04] Ethiopia works to change its health delivery system.

[28:10] What's the biggest opportunity for the Gates Foundation?

[28:57] It is possible for anyone around the world to make a difference.

[29:20] Advice for women who want to become CEOs and innovators: Keep learning!

[30:40] Ask for help.

[31:23] Be willing to take risks.

[32:39] Defining point in Dr. Desmond-Hellmann’s career: cancer-fighting breakthrough drug Herceptin.

 

Mentioned in This Episode:

CDC Foundation

Answer this episode’s question What is your favorite thing to do to recharge after a busy day? Email your answer to [email protected] to win some Contagious Conversations merchandise.

For more information about this episode go to Contagious Conversations.

...more
View all episodesView all episodes
Download on the App Store

Contagious ConversationsBy CDC Foundation

  • 4.7
  • 4.7
  • 4.7
  • 4.7
  • 4.7

4.7

67 ratings


More shows like Contagious Conversations

View all
Reveal by The Center for Investigative Reporting and PRX

Reveal

8,120 Listeners

Hidden Brain by Hidden Brain, Shankar Vedantam

Hidden Brain

43,270 Listeners

Code Switch by NPR

Code Switch

14,493 Listeners

Up First from NPR by NPR

Up First from NPR

56,155 Listeners

It's Been a Minute by NPR

It's Been a Minute

8,915 Listeners

KFF Health News' 'What the Health?' by KFF Health News

KFF Health News' 'What the Health?'

469 Listeners

Immune by Vincent Racaniello

Immune

269 Listeners

The Nocturnists by The Nocturnists

The Nocturnists

597 Listeners

An Arm and a Leg by An Arm and a Leg

An Arm and a Leg

1,078 Listeners

Throughline by NPR

Throughline

15,861 Listeners

America Dissected by Incision Media LLC

America Dissected

4,474 Listeners

Tradeoffs by Tradeoffs

Tradeoffs

391 Listeners

Short Wave by NPR

Short Wave

6,221 Listeners

Public Health On Call by The Johns Hopkins Bloomberg School of Public Health

Public Health On Call

618 Listeners

Consider This from NPR by NPR

Consider This from NPR

5,974 Listeners